Key result
Pharmacotherapy for heparin-induced thrombocytopenia lacks a single standard practice, though prompt management is essential as 50-60% of patients with HIT manifest acute thrombosis.
Population
Patients with heparin-induced thrombocytopenia, including special populations
Design
Review
Authors
Loading...
Supports individualized HIT therapy; leaves open standardization and comparative trials.
This review highlights the complexity of managing heparin-induced thrombocytopenia and emphasizes individualized anticoagulant therapy while strictly avoiding warfarin monotherapy.
Dager et al. (2003) conducted a review in Heparin-induced thrombocytopenia (HIT). Pharmacotherapy was evaluated. Pharmacotherapy for heparin-induced thrombocytopenia lacks a single standard practice, though prompt management is essential as 50-60% of patients with HIT manifest acute thrombosis.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: